Equity Profile

DYN

Dyne Therapeutics, Inc.

Health CareBiotechnology$3.2B

Jul27Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract more customers, which is crucial for a biotech firm.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DYN Q2-2026 Earnings Preview

Context

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Dyne is particularly relevant as it aims to address unmet medical needs through its specialized drug development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In Q1 2026, Dyne reported an EPS of -$0.73, slightly beating expectations of -$0.74. The stock reacted positively, gaining 4.83% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Dyne's upcoming earnings report, especially given its recent EPS beat. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If Dyne continues to show improvement in its EPS and provides positive updates on its drug development pipeline, the stock could see significant gains.

Bear Case

On the other hand, if the company fails to meet expectations or provides no clear path to profitability, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can Dyne provide on its drug development pipeline?

Investors will be looking for clarity on the progress and potential success of Dyne's therapies, which are critical for future revenue.

Will there be any guidance on expected revenue for the upcoming quarters?

Revenue guidance is crucial for assessing the company's growth trajectory and overall financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Dyne's drug pipeline to deliver significant breakthroughs, which could lead to unexpected revenue growth.

Supporting Evidence

Dyne has a history of beating EPS estimates, suggesting stronger underlying performance than anticipated.

The options market indicates a high implied move, reflecting investor uncertainty that could be resolved positively.

Insider selling could reflect individual strategies rather than company performance, which may mislead market sentiment.

Key Risk

If Dyne provides strong updates on its drug pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the backdrop of uncertainty in revenue and drug pipeline developments.

Bull Confirmed If

A clear indication of progress in drug development and a positive revenue outlook would support a bullish view.

Bear Confirmed If

Failure to provide any guidance or disappointing updates on drug development could confirm bearish sentiments.

Pre-Earnings Positioning

Options Market

Implied Move

±21.29%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±35.4% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.5%

Calls (4K)P/C Ratio: 1.91Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 30 (47%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 30 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.6%, with a raw directional average of +2.5% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$25.5M

1,282,115 sh

2 insiders

Net

$25.5M

Net selling

Most Active Insiders· 23 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats expectations and raises guidance, history suggests a positive reaction, potentially around a 5.96% increase.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors digest the information.

Miss

Should Dyne miss expectations, history suggests a potential decline, averaging around 9.27% in similar scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in the pipeline.
2Any guidance on expected revenue for the next quarter.
3Insights into the company's strategic direction and market positioning.
4Management's commentary on competitive landscape and potential challenges.
5Details on any partnerships or collaborations that could impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aon plc

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract more customers, which is crucial for a biotech firm.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DYN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In Q1 2026, Dyne reported an EPS of -$0.73, slightly beating expectations of -$0.74. The stock reacted positively, gaining 4.83% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Dyne's upcoming earnings report, especially given its recent EPS beat. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If Dyne continues to show improvement in its EPS and provides positive updates on its drug development pipeline, the stock could see significant gains.

Bear Case

On the other hand, if the company fails to meet expectations or provides no clear path to profitability, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can Dyne provide on its drug development pipeline?

Investors will be looking for clarity on the progress and potential success of Dyne's therapies, which are critical for future revenue.

Will there be any guidance on expected revenue for the upcoming quarters?

Revenue guidance is crucial for assessing the company's growth trajectory and overall financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Dyne's drug pipeline to deliver significant breakthroughs, which could lead to unexpected revenue growth.

Supporting Evidence

Dyne has a history of beating EPS estimates, suggesting stronger underlying performance than anticipated.

The options market indicates a high implied move, reflecting investor uncertainty that could be resolved positively.

Insider selling could reflect individual strategies rather than company performance, which may mislead market sentiment.

Key Risk

If Dyne provides strong updates on its drug pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the backdrop of uncertainty in revenue and drug pipeline developments.

Bull Confirmed If

A clear indication of progress in drug development and a positive revenue outlook would support a bullish view.

Bear Confirmed If

Failure to provide any guidance or disappointing updates on drug development could confirm bearish sentiments.

Pre-Earnings Positioning

Options Market

Implied Move

±21.29%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±35.4% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.5%

Calls (4K)P/C Ratio: 1.91Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 30 (47%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$25.5M

1,282,115 sh

2 insiders

Net

$25.5M

Net selling

Most Active Insiders· 23 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats expectations and raises guidance, history suggests a positive reaction, potentially around a 5.96% increase.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors digest the information.

Miss

Should Dyne miss expectations, history suggests a potential decline, averaging around 9.27% in similar scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in the pipeline.
2Any guidance on expected revenue for the next quarter.
3Insights into the company's strategic direction and market positioning.
4Management's commentary on competitive landscape and potential challenges.
5Details on any partnerships or collaborations that could impact growth.